Yuhan USA
Yuhan USA Corporation is the US commercialization arm of Korean pharma Yuhan Corporation, providing regulatory, sales, marketing, and logistics support to bring partner pharmaceutical and digital health products — including lung cancer therapy Leclaza and AI-based cardiac monitoring devices — into the US healthcare market.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Yuhan USA does
Yuhan USA Corporation is a Cambridge, Massachusetts-based subsidiary of the South Korean pharmaceutical company Yuhan Corporation (KOSPI: 000100), operating as the parent group's US market entry and commercialization arm. Founded in 2018 and staffed at 1-10 employees, it provides local US infrastructure — sales channel development, localized marketing, FDA regulatory approval support, and logistics operations — for partner healthcare products seeking to enter the US market.
The subsidiary's portfolio centers on two pillars. In pharmaceuticals, it supports US commercialization of parent-pipeline assets such as Leclaza, a lung cancer therapy that received FDA approval in August 2024. In digital health, it executed a strategic partnership with Huinno in March 2026 to bring AI-based cardiac monitoring products (MEMO Patch M, MEMO Cue, MEMO Care) and the Vital-PICASO clinical prediction platform into US hospital and provider channels. Underlying technology at the parent level includes AI-based drug development platforms and next-generation targeted protein degradation (TPD) technology aimed at first-in-class candidates.
Revenue mechanics rely on pharmaceutical product commercialization (including royalties/licenses from partnered drugs) plus partnership-driven fee or margin contributions from digital health distribution. Yuhan Corporation's roughly 250 billion won annual R&D outlay and its pivot toward NewCo/co-development structures with global pharma partners suggest upstream pipeline scaling, while Yuhan USA absorbs the US commercialization workload. Customer base is concentrated in healthcare providers and patients, with global pharma companies as a secondary partner segment.
Yuhan USA firmographics
Firmographics- Name
- Yuhan USA
- Legal name
- Yuhan USA Corporation
- Website
- https://yuhan-usa.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Yuhan USA Corporation is the US commercialization arm of Korean pharma Yuhan Corporation, providing regulatory, sales, marketing, and logistics support to bring partner pharmaceutical and digital health products — including lung cancer therapy Leclaza and AI-based cardiac monitoring devices — into the US healthcare market.
- Ownership category
- akta.pro rank
Yuhan USA industry classification
Industry- Product category
- Pharmaceutical Commercialization Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- OTC & Consumer Health Distributors (HLAIAJAC)
- akta.pro secondary industry
- Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)
Keywords
Where Yuhan USA is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Yuhan USA business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Pharmaceutical drug development and sales: Yuhan generates revenue through development and commercialization of pharmaceutical products, including lung cancer therapy Leclaza approved by FDA in August 2024. The company is pivoting to co-development and NewCo entity structures to share risk and revenue with global pharmaceutical partners for late-stage clinical trials.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Yuhan USA product offering
Product offeringCore offering
Yuhan USA is the US commercialization arm of Yuhan Corporation, providing sales channel development, localized marketing, regulatory approval support, and logistics operations for partner pharmaceutical and digital health products entering the US healthcare market. The company supports co-development arrangements and licenses pharmaceutical innovations such as FDA-approved lung cancer therapy Leclaza for the US market.
Product overview
Yuhan USA serves as the US commercialization arm for both pharmaceutical and digital health products. In pharmaceuticals, the flagship product is Leclaza (FDA-approved August 2024 for lung cancer), representing Yuhan's breakthrough in the US market. In digital health, Yuhan USA partners with Huinno to commercialize AI-driven cardiac monitoring solutions including MEMO Patch M, MEMO Cue, MEMO Care, and the Vital-PICASO clinical prediction platform, leveraging Yuhan USA's local sales channels, marketing, regulatory approval support, and logistics capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Leclaza (Lazcluze)
- US Commercialization Services
- MEMO Patch M
- MEMO Cue
- MEMO Care
- Vital-PICASO
Quantifiable outcome
- Lung cancer therapy Leclaza received FDA approval in August 2024
- +1 more outcomes
Companies that use Yuhan USA
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Yuhan USA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Yuhan USA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HuinnocoreHuinno, an AI-based cardiac monitoring startup, has partnered with Yuhan USA Corporation to expand its ECG monitoring solutions into the US digital healthcare market. The partnership covers sales channel development, localized marketing, regulatory approval support, and logistics operations for Huinno's product lineup including MEMO Patch M, MEMO Cue, MEMO Care, and the clinical prediction platform Vital-PICASO. The collaboration combines Huinno's AI-driven monitoring technologies with Yuhan USA's local commercialization capabilities to accelerate adoption within the US healthcare system.
Scale indicators3 records
Recent moves4 records
Expansion highlights5 records
Yuhan USA competitors and assessment
Company assessmentBroad incumbents
- Dr. Reddy's Laboratories: India-based multinational with a substantial US pharmaceutical generics and specialty business. Broad incumbent peer on international-to-US pharma commercialization at scale.
- Sun Pharmaceutical Industries: India-headquartered global pharma with a sizable US subsidiary commercializing a broad specialty and generics portfolio. Comparable as a large international pharma with US commercialization infrastructure and partnership activity.
- Hikma Pharmaceuticals: International pharmaceutical company with a large US specialty/generics distribution business. Broader peer for US pharmaceutical distribution scale, channel relationships, and institutional customer access.
Emerging players
- iRhythm Technologies: US-based digital cardiac monitoring company (e.g., Zio patch) — directly analogous to the Huinno MEMO Patch / ECG solutions Yuhan USA is commercializing. Relevant peer for the digital-health portion of Yuhan USA's portfolio.
Regional players
- Boryung Pharmaceutical: Korean pharmaceutical company with US commercialization ambitions and licensed products in the US. Comparable as another Korea-rooted company pursuing US pharmaceutical distribution and partnerships.
- Chong Kun Dang Pharmaceutical: Korean pharmaceutical manufacturer with selective US market entry efforts. Comparable regional Korean-pharma peer building US-side distribution and partnership capabilities.
Direct peers
- Celltrion: Korean biopharmaceutical company with a US subsidiary commercializing biosimilars across regulatory, distribution and sales channels. Highly comparable as a Korea-headquartered firm scaling into US pharmaceutical markets.
- Daewoong Pharmaceutical: Korean pharmaceutical company with US presence focused on bringing parent-company products to the US market via local commercialization and partnership deals — closely comparable model to Yuhan USA.
- Hanmi Pharmaceutical: Korean pharmaceutical company with active US commercialization subsidiary. Direct peer on cross-border pharma commercialization: a Korean parent with established US distribution/partnerships model for prescription and specialty drugs.
- LG Chem Life Sciences: Korean life sciences business pursuing US market entry for parent-developed innovative drugs, including partnerships and co-development models — comparable in the cross-border pharma commercialization structure.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Yuhan USA social profiles
Digital presenceYuhan USA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yuhan USA leadership team
Management profileNumber of profiles
Yuhan USA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yuhan USA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yuhan USA
What does Yuhan USA do?
Yuhan USA is the US commercialization arm of Yuhan Corporation, providing sales channel development, localized marketing, regulatory approval support, and logistics operations for partner pharmaceutical and digital health products entering the US healthcare market. The company supports co-development arrangements and licenses pharmaceutical innovations such as FDA-approved lung cancer therapy Leclaza for the US market.
Is Yuhan USA a public or private company?
Yuhan USA is a private company. It is classified as corporate owned and is currently operating.
When was Yuhan USA founded?
Yuhan USA was founded in 2018. It employs 1 to 10 people.
Where is Yuhan USA based?
Yuhan USA is headquartered in Cambridge, United States, in the North America region.
How does Yuhan USA make money?
One revenue line is on record: pharmaceutical drug development and sales.
Who are Yuhan USA's main competitors?
Broad incumbents on record are Dr. Reddy's Laboratories, Sun Pharmaceutical Industries and Hikma Pharmaceuticals. iRhythm Technologies is listed as an emerging player. Regional players are Boryung Pharmaceutical and Chong Kun Dang Pharmaceutical. Direct peers are Celltrion, Daewoong Pharmaceutical, Hanmi Pharmaceutical and LG Chem Life Sciences.
Does Yuhan USA have an API?
No public API is recorded for Yuhan USA.
What industry is Yuhan USA in?
Yuhan USA's product category is Pharmaceutical Commercialization Services. Its primary akta.pro industry code is HLAIAJAC, OTC & Consumer Health Distributors, with a secondary code of BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation. Its NAICS code is 42421 and its SIC code is 5122.